Technical Report No. 84

Integrating Data Integrity Requirements into Manufacturing & Packaging Operations
Integrating Data Integrity Requirements into Manufacturing & Packaging Operations

Authors

Els Poff, Merck (Chair)
James Curry, PhD, Teva Pharmaceuticals
John Grealis, PhD, Novartis
Anne Pericone, Johnson & Johnson
Susan Schniepp, Regulatory Compliance Associates Inc.
Nader Shafiei, PhD, Sanofi
Ronald Tetzlaff, PhD, Parexel Consulting
Anthony Warchut, AC Warchut GMP Consulting

Contributors

Jeffrey Broadfoot, Emergent BioSolutions, Inc.
Derek Glover, Mylan
Maryann Gribbin, Faith & Royale Consultants
Tina Morris, PhD, American Association of Pharmaceutical Scientists
Rebecca Parrilla, U.S. Food and Drug Administration
Carmelo Rosa, PsyD, U.S. Food and Drug Administration
Anil Sawant, PhD, Merck
Christopher Smalley, PhD, ValSource, LLC
Integrating Data Integrity Requirements into Manufacturing & Packaging Operations

Technical Report No. 84

ISBN: 978-1-945584-19-0
© 2020 Parenteral Drug Association, Inc.
All rights reserved.

PDA®
Parenteral Drug Association
Table of Contents

1.0 INTRODUCTION AND SCOPE ........................................ 1
  1.1 Purpose ......................................................... 1
  1.2 Scope .......................................................... 2

2.0 GLOSSARY AND ABBREVIATIONS .............................. 2
  2.1 Abbreviations .................................................. 5

3.0 DATA INTEGRITY TRENDS AT INTERNATIONAL DRUG MANUFACTURERS ........................................... 6
  3.1 Historical Perspective .......................................... 6
  3.2 Regulatory Guidance .......................................... 10
  3.3 Industry Best Practices ........................................ 10

4.0 QUALITY RISK MANAGEMENT APPLIED TO DATA INTEGRITY ......................................................... 11
  4.1 Considerations in Assessing Risk ............................... 11
  4.2 Data Integrity Risk Management Model ......................... 13
  4.3 Data Vulnerability (9-Box) ..................................... 15
  4.4 Using the Data Vulnerability Grid .............................. 17

4.5 Data Process Flow Maps ........................................... 19

5.0 DATA INTEGRITY CONTROLS .................................... 21
  5.1 Potential Differentiation of Controls ............................ 22
  5.2 Methodology Used to Determine Differentiated Controls .................... 23
  5.3 Areas of Differentiated Data Integrity Controls ............ 25

6.0 CONTROLS FOR BIG DATA AS IT RELATES TO DATA INTEGRITY ....................................................... 38

7.0 REFERENCES ...................................................... 39

8.0 APPENDIX I: EXAMPLES — HOW TO USE THE 9-BOX VULNERABILITY GRID ........................................... 40
  8.1 API Process Examples ........................................... 40
  8.2 Finished Dosage Form Examples ................................. 46
  8.3 Sterility Assurance Examples .................................... 50
  8.4 Tablet Packaging Process Examples ............................ 54
  8.5 References for Appendix I ....................................... 57

FIGURES AND TABLES INDEX

Figure 3.1.1-1 FDA Warning Letters—DI Issues Related to Production Activities by Country of Inspected Location .......... 7
Figure 3.1.1-2 Incidence of Warning Letters Citing Production Activities by Product Type (API vs Finished Pharmaceuticals) ...... 8
Table 3.1.3-1 EU Non-Compliance Reports—DI ..................... 8
Table 4.1.1-1 Human Factors Matrix .................................. 12
Figure 4.2-1 Data Integrity Risk Management Model .................. 14
Table 4.2.1-1 Classification of Data Criticality ....................... 15
Table 4.2.2-1 Data Control Levels .................................. 15
Table 4.3-1 Data Vulnerability Grid (9-Box) – Example for Data Management Technology Controls .................. 16
Table 4.4-1 Potential Areas of Data Integrity Vulnerability .......... 18
Figure 4.5.1-1 Case 1: Granulation Operation (Paper-Based Manual Process without Automated Alerts) .................. 21
Figure 4.5.1-2 Case 2: Granulation Operation (PLC-Controlled Process with Automated Alerts) ............................... 21
Figure 5.2-1 Methodology Used to Determine Differentiated Controls ........................................... 23
Table 5.2-1 Categories Where Different Levels of Data Integrity Controls are Acceptable based on Criticality ........... 24
Table 5.3.1-1 Data Integrity Control Grid for Storage of and Access to Completed and Archived Paper Records ............. 26
Table 5.3.2-1 Data Integrity Control Grid for Issuance and Reconciliation of Paper Records ............................... 27
Table 5.3.3.1-1 Data Integrity Control Grid for Data Accuracy when Manually Recording without a Controlled Second Format .................................. 28
Table 5.3.3.2-1 Data Integrity Control Grid for Data Accuracy when Transcribing Manually Recorded Data into an Electronic System .................................. 29
Table 5.2.3.3-1 Data Integrity Control Grid for True Copy (Paper to Electronic) ...................................... 30
Table 5.3.4-1 Data Integrity Control Grid for Access Controls for Electronic Systems ............................. 31
Table 5.3.5.1-1 ATRA Final Score and Frequency Review ........................................... 33
Table 5.3.5.2-1 Example of How ATRA Tool is Used to Score a Filter Integrity Tester ....................... 35

www.pda.org/bookstore
<table>
<thead>
<tr>
<th>Table 5.3.6-1</th>
<th>Data Integrity Control Grid for Data Backup for System with Limited Storage Capacity</th>
<th>Table 8.3-1</th>
<th>Example 6: Low Criticality — Humidity Monitoring During Sieving of a Drug Substance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 5.3.7.1-1</td>
<td>Data Integrity Control Grid for Data Export for Generation of Reports and Records</td>
<td>Table 8.3-2</td>
<td>Example 7: High Criticality — Filter Integrity Testing at the Point of Fill (Post-Use)</td>
</tr>
<tr>
<td>Table 5.3.7.2-1</td>
<td>Data Integrity Control Grid for Data Transfer and Migration Between Electronic Systems</td>
<td>Table 8.3-3</td>
<td>Example 8: Medium Criticality — Filter Identity Verification at the Point of Fill (Pre-Use—Post-Sterilization)</td>
</tr>
<tr>
<td>Table 8.1-1</td>
<td>Example 1: High Criticality API Reaction Controls Impurity Level</td>
<td>Table 8.3-4</td>
<td>Overview of the Packaging Process</td>
</tr>
<tr>
<td>Table 8.1-2</td>
<td>Example 2: Medium Criticality — Drying of API (LOD not a CQA)</td>
<td>Table 8.4-1</td>
<td>Example 10: High &amp; Medium Criticality — Tablet Packaging</td>
</tr>
<tr>
<td>Table 8.1-3</td>
<td>Example 3: Low Criticality — Small Molecule API Batch-to-Batch Cleaning of Equipment within a Campaign</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table 8.2-1</td>
<td>Example 4: High Criticality — Humidity Monitoring During Sieving of a Drug Substance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table 8.2-2</td>
<td>Example 5: Medium Criticality — Humidity Monitoring During Sieving of a Drug Substance</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>